Table 3.
Lifetime attributable risks (LAR) for second cancer incidences assuming an 8/14-year old female/male treated with 54 Gy (Gy[RBE]) target dose (spine lesion; field 6). For breast, instead of combining the two transport models we quote the estimates separately.
| Organs | LAR (%) |
Baseline(%) | ||
|---|---|---|---|---|
| Passive scattered proton therapy | IMRT | Proton beam scanning | ||
| Brain | 0.01/<0.01 | 0.08/0.04 | <0.01/<0.01 | 0.56/0.65 |
| Pharynx | 0.02/0.01 | 0.02/0.03 | 0.01/<0.01 | 0.67/1.41 |
| Larynx | 0.01/0.01 | 0.01/0.01 | <0.01/<0.01 | 0.15/0.61 |
| Thyroid | 0.18/0.02 | 0.21/0.01 | 0.04/<0.01 | 1.1/0.38 |
| Bronchi | 0.59/0.28 | 0.19/0.16 | 0.06/0.04 | 6.67/7.76 |
| Breast EAR | 0.68/- | 0.55/- | 0.13/- | 13/- |
| Breast ERR | 0.40/- | 0.32/- | 0.07/- | 13/- |
| Esophagus | 0.05/0.06 | 0.02/0.06 | 0.01/0.01 | 0.24/0.75 |
| Lung | 1.16/0.33 | 0.59/0.23 | 0.16/0.05 | 6.67/7.75 |
| Rectosigmoid Wall | 0.62/0.40 | 0.36/0.38 | 0.10/0.01 | 5.38/5.67 |
| Uterus/Prostate | 0.06/0.06 | 0.036/0.05 | 0.01/0.01 | 2.5/16.01 |
| Ovaries/Testes | 0.13/0/04 | 0.074/0.04 | 0.02/0.01 | 1.42/0.37 |
| Bladder Wall | 0.29/0.21 | 0.14/0.13 | 0.04/0.03 | 1.25/3.98 |